Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$172.27 USD

172.27
2,319,853

+11.25 (6.99%)

Updated May 14, 2024 04:00 PM ET

After-Market: $172.26 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avantor (AVTR) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Avantor (AVTR) is likely to have gained during the third quarter on the back of robust performance of its end markets.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q2 sales.

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Baxter (BAX) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.

DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

What's in Store for West Pharmaceutical's (WST) Q3 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Continued strong adoption of Invisalign Clear Aligners and iTero scanners is expected to contribute to Align Technology's (ALGN) third-quarter 2021 results.

Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade

by Zacks Equity Research

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

ResMed (RMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).

Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

by Zacks Equity Research

Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.

Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev

by Zacks Equity Research

Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.

Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

    Insulet (PODD) Q2 Earnings Lag Estimates

    by Zacks Equity Research

    Insulet (PODD) delivered earnings and revenue surprises of -16.67% and 2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Earnings Preview: Insulet (PODD) Q2 Earnings Expected to Decline

    by Zacks Equity Research

    Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5

    by Zacks Equity Research

    Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.

    Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat

    by Zacks Equity Research

    Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

    Insulet (PODD) Reports Break-Even Earnings for Q1

    by Zacks Equity Research

    Insulet (PODD) delivered earnings and revenue surprises of -100.00% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Insulet (PODD) Up 0.5% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Insulet's (PODD) Omnipod 5 Pivotal Trial Outcome Favorable

    by Zacks Equity Research

    Insulet's (PODD) Omnipod 5 pivotal study showed improvement in glucose control, verified by notable reduction in HbA1c and enhanced time in range together with the lowest rates of hypoglycemia.

    Debanjana Dey headshot

    4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic

    by Debanjana Dey

    Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.

      Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

      by Zacks Equity Research

      Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

      Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens

      by Zacks Equity Research

      Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.